Castrate Sensitive Prostate Cancer Market

DelveInsight’s ‘Castrate-Sensitive Prostate Cancer (CSPC) Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the CSPC, historical and forecasted epidemiology as well as the CSPC market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.


The CSPC market report provides current treatment practices, emerging drugs, CSPC market share of the individual therapies, current and forecasted CSPC market size from 2017 to 2030 segmented by seven major markets. The Report also covers current CSPC treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan


Study Period: 2017–2030

CSPC: Disease Understanding and Treatment Algorithm

CSPC Overview

Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. According to the Cancer Treatment Centres of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells. The exact cause of prostate cancer is unknown.


However, several things can increase the risk of developing this condition like age, family history, diet, high testosterone level, genome changes, and race.

In the majority of the cases, the symptoms of prostate cancer are not apparent in the early stages of the disease. The symptoms of prostate cancer may be different for each man, and other conditions may cause some of these symptoms like blood in semen, erectile dysfunction, painful ejaculation, pain in pelvic area, and numbness in legs.


“Patients who have never received i.e. are sensitive to ADT known as hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC). And it was accessed that around 78% of biochemical recurrence/ progressive cases are non-metastatic CSPC/ HSPC.”


CSPC Diagnosis

Patients undergo regular prostate cancer screening before symptoms appear. Screening may involve one or more of the following tests: prostate-specific antigen (PSA), digital rectal exam (DRE), prostate ultrasound, prostate MRI, prostate Mp-MRI.


CSPC Treatment

Prostate cancer is the second most common cancer in men can be categorized into castrate-sensitive (castration-sensitive prostate cancer [CSPC], and castration-resistant prostate cancer (mCRPC). This type of cancer only considered to be CSPC if it responds to medical or surgical treatment to lower a patient’s testosterone levels. For the treatment of CSPC, Androgen-deprivation therapy (ADT) has been the cornerstone of therapy. However, most metastatic CSPC ( mCSPC/HSPC ) cannot be cured by ADT, and re‐emerges as metastatic castration-resistant prostate cancer (mCRPC). The treatment landscape of CSPC was not evolved until recent years. Docetaxel was the first chemotherapy for metastatic prostate cancer that showed a survival benefit. Since then pharmaceutical industries had indulged themselves into the investigation of new therapies for this type of Prostate Cancer. Lately, developments of androgen receptor targeted therapies have influenced the treatment paradigm of CSPC/HSPC

CSPC Epidemiology

The CSPC epidemiology division provides the insights about historical and current CSPC patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

The total cases of CSPC in the 7MM were found to be 763,077 in 2017 which is expected to grow during the study period, i.e., 2017–2030.

The disease epidemiology covered in the report provides historical as well as forecasted CSPC epidemiology [segmented as Total Prevalent Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer, Age-specific Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer by Clinical Stages, Total Non-metastatic and Metastatic Cases of CSPC, and Total Treated Cases of Non-metastatic and Metastatic CSPC] scenario of CSPC in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.


Country Wise- CSPC Epidemiology

Estimates show that the highest cases of CSPC were in the United States, followed by Germany, France, Japan, and Italy in 2017.

CSPC Drug Chapters

Drug chapter segment of the CSPC report encloses the detailed analysis of CSPC marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the CSPC clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


CSPC Marketed Drugs

Erleada (apalutamide): Janssen Pharmaceuticals

Erleada (apalutamide; Janssen Pharmaceutical) is a next-generation oral androgen receptor (AR) inhibitor that blocks the androgen signaling pathway in prostate cancer cells. It is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC/HSPC).

In January 2020, the European Commission has approved apalutamide (Erleada) for use in combination with androgen deprivation therapy (ADT) for the treatment of adult men with metastatic hormone-sensitive prostate cancer. The EC approval is based on data from the phase III TITAN study, which assessed the addition of apalutamide to ADT in a broad range of patients with mHSPC, regardless of disease volume, prior treatment with docetaxel or staging at initial diagnosis.


Xtandi (Enzalutamide): Astellas Pharma/Pfizer

It is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. In December 2019, the US FDA granted approval to Xtandi (enzalutamide; Astellas Pharma) for use in the treatment of patients with metastatic CSPC. Prior to this, Xtandi was approved for castration-resistant prostate cancer. This approval was based on findings from the ARCHES clinical trial. The median rPFS rates in the Xtandi were not reached and for placebo arms was 19.4 months, respectively. In addition to this, in ARCHES trial statistically significant improvement in time to initiation of a new antineoplastic therapy with enzalutamide vs. placebo. The most common adverse reactions that occurred more frequently in enzalutamide-treated patients in ARCHES were hot flush, asthenia/fatigue, hypertension, fractures, and musculoskeletal pain.

Products detail in the report…

CSPC Emerging Drugs

Keytruda (pembrolizumab): Merck Sharp & Dohme

Keytruda, also known as pembrolizumab, is a PD-1 blocking antibody. It is product of Merck Sharp & Dohme. It is mainly used for cancers that are advanced, have spread to other parts of the body or are not responding to other treatments. In some cancers, it is only given to patients whose tumors produce high levels of a protein known as PD-L1. It is approved for multiple types of cancer. This is currently being investigated in Phase III clinical trials in combination with Enzalutamide for the treatment of patients affected by mHSPC.


Opdivo (nivolumab): Bristol-Myers Squibb

Opdivo (Nivolumab) by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. This drug is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.


BMS is working on assessing the clinical activity seen with Opdivo in combination with in combination with Ipilimumab, Docetaxel, and ADT for mHSPC in Phase II/III clinical trial.


Relugolix: Myovant Sciences

Myovant Sciences also investigating their candidate Relugolix for Androgen-sensitive advanced prostate cancer. A phase III HERO study (NCT03085095; Recruiting) currently ongoing to determine the benefit and safety of Relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (≤ 50 ng/dL [1.7 nmol/L] in participants with androgen-sensitive advanced prostate cancer. This is an international, randomized, open-label, parallel group efficacy and safety study.


Topsalysin (PRX302): Sophiris Bio

Topsalysin (PRX302), an investigative agent of Sophiris Bio for localized prostate cancer. It is first-in-class transmembrane pore-forming protein, was genetically modified to be activated only by enzymatically-active PSA, which is produced in large quantities within the prostate of men with prostate cancer.


ProstAtak: Advantagene

Advantagene is developing ProstAtak for the treatment of patients suffering from prostate cancer. ProstAtak jump-starts the body’s own immune system to detect and destroy recurring cancer cells. The treatment is done together with standard radiation therapy. Last year, Candel Therapeutics (Advantagene) announced that it has completed the enrollment of the "ULYSSES" trial, a Phase II study of ProstAtak for prostate cancer patients choosing Active Surveillance (PrTK04- NCT02768363). However, enrollment is still open for prostate cancer patients choosing radiation therapy as their primary treatment (PrTK03- NCT01436968).

Products detail in the report…

CSPC Market Outlook

Key Findings

The market size of CSPC in the 7MM countries is expected to increase by 2030 from USD 638 million in 2017, which is expected to increase during study period (2017–2030).


The United States Market Outlook

In 2017, the total market size of CSPC therapies was USD 415 million in the United States which is expected to increase in the study period (2017–2030).


EU-5 Countries: Market Outlook

In 2017, the total market size of CSPC therapies was USD 180 million in the EU-5 countries which is expected to increase in the study period (2017–2030).


Japan Market Outlook

The total market size of CSPC therapies in Japan was USD 43 million in 2017.

CSPC Pipeline Development Activities

The drugs which are in pipeline include:

1. Keytruda (Pembrolizumab/MK-3475) + Enzalutamide + ADT: Phase III

2. Opdivo (nivolumab) ± ADT ± docetaxel ± Ipilimumab: Phase II/III

3. Relugolix: Phase III

4. ProstAtak (AdV-tk + valacyclovir): Phase III

5. PRX302 (topsalysin): Phase II

6. RV001: Phase III

Product details and complete list of emerging products will be provided in the full report...

CSPC Drugs Uptake

  • In mCSPC, currently market is dominated by hormonal therapies, mainly the first-generation hormonal therapies.
  • Erleada owing to better clinical profile expected to generate the maximum sales within the metastatic CSPC.
  • Like mCSPC, in nmCSPC/HSPC also market is also mainly dominated by first generation hormonal therapies.

Access and Reimbursement Scenario in CSPC Therapies

  • Health technology assessment (HTA) agencies are evaluating the drugs based on segments they are targeting. In case of CSPC setting, drugs will be compared against the cheaper hormonal therapies especially first-generation therapies.
  • And it will be challenging for the drugs to show add on benefit compared to first generation hormonal therapies in given price. And unavailability of precedent in this setting makes it even more difficult to predict the HTA agencies decisions.

KOL-Views

To keep up with current market trends, we take KOLs and SME’s opinion working in CSPC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or CSPC market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the CSPC Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of CSPC, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the CSPC epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for CSPC is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of CSPC market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global CSPC market.

Report Highlights

  • In the coming years, CSPC market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence CSPC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for CSPC. Launch of emerging therapies, will significantly impact the CSPC market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CSPC.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

CSPC Report Insights

  • Patient Population
  • Therapeutic Approaches
  • CSPC Pipeline Analysis
  • CSPC Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

CSPC Report Key Strengths

  • 11 Years Forecast
  • 7MMCoverage
  • CSPC Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

CSPC Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the CSPC Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the CSPC total market Size as well as market size by therapies across the 7MM during the study period (2017–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest CSPC market size during the study period (2017–2030)?
  • At what CAGR, the CSPC market is expected to grow in 7MM during the study period (2017–2030)?
  • What would be the CSPC market outlook across the 7MM during the study period (2017–2030)?
  • What would be the CSPC market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • CSPC patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the CSPC market?


Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of the CSPC?
  • What is the historical CSPC patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of CSPC in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CSPC?
  • Out of all the 7MM countries, which country would have the highest prevalent population of CSPC during the study period (2017–2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017–2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of CSPC?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of CSPC along with the approved therapy?
  • What are the current treatment guidelines for the treatment of CSPC in the US, Europe and Japan?
  • What are the CSPC marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of CSPC?
  • How many therapies are developed by each company for the treatment of CSPC?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of CSPC?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CSPC therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for CSPC and their status?
  • What are the key designations that have been granted for the emerging therapies for CSPC?
  • What is the global historical and forecasted market of CSPC?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the CSPC market.
  • To understand the future market competition in the CSPC market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for CSPC in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for CSPC market.
  • To understand the future market competition in the CSPC market.

1. Key Insights

2. Executive Summary of CSPC/HSPC

3. SWOT Analysis of CSPC/HSPC

4. CSPC/HSPC: Market Overview at a Glance

5. CSPC/HSPC: Disease Background and Overview

5.1. Introduction

5.1.1. Signs and Symptoms of Prostate Cancer

5.1.2. Risk Factors and Causes of Prostate Cancer

5.1.3. Pathophysiology of Prostate Cancer

5.1.4. Prostate Neoplasia

5.1.5. Genetics of Prostate Cancer

6. Diagnosis

6.1. Screening Tests for Prostate Cancer

6.2. Tests to Diagnose Prostate Cancer

6.3. Stages and Grades of Prostate Cancer

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM

7.3.2. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM

7.3.3. Total Non-metastatic and Metastatic Cases of CSPC/HSPC in the 7MM

7.3.4. Total Treated cases of Non-metastatic CSPC/HSPC Patients in the 7MM

7.3.5. Total Treated Cases of Metastatic CSPC/HSPC Patients in the 7MM

7.4. The United States Epidemiology

7.4.1. Total Diagnosed Cases of Prostate Cancer in the United States

7.4.2. Age-specific Cases of Prostate Cancer in the United States

7.4.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States

7.4.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC in the United States

7.4.5. Total Treated cases of Non-metastatic CSPC/HSPC in the United States

7.4.6. Total Treated Cases of Metastatic CSPC/HSPC in the United States

8. EU-5 Country-wise Epidemiology

8.1. Germany

8.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Germany

8.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany

8.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany

8.1.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC in Germany

8.1.5. Total Treated cases of Non-metastatic CSPC/HSPC in Germany

8.1.6. Total Treated Cases of Metastatic CSPC/HSPC in Germany

8.2. France

8.2.1. Total Diagnosed Prevalent cases of Prostate Cancer in France

8.2.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in France

8.2.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France

8.2.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC in France

8.2.5. Total Treated cases of Non-metastatic CSPC/HSPC in France

8.2.6. Total Treated Cases of Metastatic CSPC/HSPC in France

8.3. Italy

8.3.1. Total Diagnosed Prevalent cases of Prostate Cancer in Italy

8.3.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy

8.3.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy

8.3.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC in Italy

8.3.5. Total Treated cases of Non-metastatic CSPC/HSPC in Italy

8.3.6. Total Treated Cases of Metastatic CSPC/HSPC in Italy

8.4. Spain

8.4.1. Total Diagnosed Prevalent cases of Prostate Cancer in Spain

8.4.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain

8.4.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain

8.4.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC in Spain

8.4.5. Total Treated cases of Non-metastatic CSPC/HSPC in Spain

8.4.6. Total Treated Cases of Metastatic CSPC/HSPC in Spain

8.5. United Kingdom

8.5.1. Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom

8.5.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom

8.5.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom

8.5.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC in the United Kingdom

8.5.5. Total Treated cases of Non-metastatic CSPC/HSPC in the United Kingdom

8.5.6. Total Treated Cases of Metastatic CSPC/HSPC in the United Kingdom

9. Japan

9.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan

9.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan

9.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan

9.1.4. Total Non-metastatic and Metastatic Cases of CSPC/HSPC in Japan

9.1.5. Total Treated cases of Non-metastatic CSPC/HSPC in Japan

9.1.6. Total Treated Cases of Metastatic CSPC/HSPC in Japan

10. Current Treatment Practices: Prostate Cancer

10.1. Treatment Algorithm of Prostate Cancer

10.2. Observation or Active Surveillance

10.3. Surgery

10.3.1. Open or Laparoscopic Radical Prostatectomy

10.3.2. Risks of Prostate Surgery

10.4. Radiation Therapy

10.4.1. Types of Radiation Therapy

10.5. Hormone Therapy

10.5.1. Types of Hormone Therapy

10.6. Immunotherapy

10.6.1. Vaccine

10.6.2. Immune checkpoint inhibitors

10.7. Chemotherapy

11. Guideline of Prostate Cancer

11.1. TheEuropean Association of Urology (EAU) Guideline for Management of Prostate Cancer: 2020

11.2. The National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer: 2019

11.2.1. Screening Guidelines

11.2.2. Genetic Testing

11.2.3. Bone Scan for Diagnosis of Metastatic Disease

11.3. Japanese Urological Association Clinical Practice Guideline for Prostate Cancer

12. Unmet Needs of Prostate Cancer

13. Marketed Therapies

13.1. Key Cross

13.2. Xtandi (Enzalutamide): Astellas Pharma

13.2.1. Product Description

13.2.2. Regulatory Milestones

13.2.3. Other Developmental Activities

13.2.4. Pivotal Clinical Trial

13.2.5. Ongoing Current Pipeline Activity

13.3. Erleada (apalutamide): Janssen Pharmaceutical

13.3.1. Product Description

13.3.2. Regulatory Milestones

13.3.3. Other Developmental Activities

13.3.4. Pivotal Clinical Trials

13.3.5. Ongoing Current Pipeline Activity

14. Emerging Therapies

14.1. Opdivo (nivolumab): Bristol-Myers Squibb

14.1.1. Product Description

14.1.2. Clinical Development

14.1.3. Safety and Efficacy

14.2. Relugolix: Myovant Sciences/Takeda

14.2.1. Product Description

14.2.2. Clinical Development

14.2.3. Safety and Efficacy

14.3. Keytruda (Pembrolizumab/MK-3475): Merck Sharp & Dohme

14.3.1. Product Description

14.3.2. Clinical Development

14.3.3. Safety and Efficacy

14.4. PRX302 (topsalysin): Sophiris Bio

14.4.1. Product Description

14.4.2. Clinical Development

14.4.3. Safety and Efficacy

14.5. RV001V: RhoVac

14.5.1. Product Description

14.5.2. Other Developmental Activities

14.5.3. Clinical Development

14.5.4. Safety and Efficacy

14.6. ProstAtak: Advantagene

14.6.1. Product Description

14.6.2. Other Developmental Activities

14.6.3. Clinical Development

14.6.4. Safety and Efficacy

15. CSPC/HSPC: Seven Major Market Analysis

15.1. Key Findings

15.2. Market Outlook: 7MM

16. 7MM Market Size

16.1. Total Market Size of CSPC in the 7MM

16.2. Total Market size of CSPC by Therapies in the 7MM

16.3. United States Market Size

16.3.1. Total Market size of CSPC in the United States

16.3.2. Total Market size of CSPC by Therapies in the United States

16.4. EU-5 Market Size

16.4.1. Germany Market Size

16.4.2. France Market Size

16.4.3. Italy Market Size

16.4.4. Spain Market Size

16.4.5. United Kingdom Market Size

16.5. Japan Market Size

16.5.1. Total Market size of CSPC in Japan

16.5.2. Total Market size of CSPC by Therapies in Japan

17. Market Access and Reimbursement of CSPC

18. Market Drivers of CSPC

19. Market Barriers of CSPC

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables:

Table 1 Summary of CSPC Market, Epidemiology, and Key Events (2017–2030)

Table 2 Genetic Changes Associated with Prostate Cancer Tumorigenesis

Table 3 Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)

Table 4 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–2030)

Table 5 Total Non-metastatic Cases of CSPC/HSPC in the 7MM (2017–2030)

Table 6 Total Metastatic Cases of CSPC/HSPC in the 7MM (2017–2030)

Table 7 Total Treated Cases of nmHSPC/CSPC in the 7MM (2017–2030)

Table 8 Total Treated Cases of nmHSPC/CSPC in the 7MM (2017–2030)

Table 9 Total Treated Cases of mHSPC/CSPC in the 7MM (2017–2030)

Table 10 Total Treated Cases of mCSPC/HSPC in the 7MM (2017–2030)

Table 11 Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)

Table 12 Age-specific Cases of Prostate Cancer in the United States (2017–2030)

Table 13 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States (2017–2030)

Table 14 Total Non-metastatic Cases of CSPC/HSPC in the United States (2017–2030)

Table 15 Total Metastatic Cases of CSPC/HSPC in the United States (2017–2030)

Table 16 Total Treated Cases of nmHSPC/CSPC in the United States (2017–2030)

Table 17 Total Treated Cases of nmHSPC/CSPC in the United States (2017–2030)

Table 18 Total Treated Cases of mHSPC/CSPC in the United States (2017–2030)

Table 19 Total Treated Cases of mCSPC/HSPC in the United States (2017–2030)

Table 20 Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Table 21 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Table 22 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany (2017–2030)

Table 23 Total Non-metastatic Cases of CSPC/HSPC in Germany (2017–2030)

Table 24 Total Metastatic Cases of CSPC/HSPC in Germany (2017–2030)

Table 25 Total Treated Cases of nmHSPC/CSPC in Germany (2017–2030)

Table 26 Total Treated Cases of nmHSPC/CSPC in Germany (2017–2030)

Table 27 Total Treated Cases of mHSPC/CSPC in Germany (2017–2030)

Table 28 Total Treated Cases of mCSPC/HSPC in Germany (2017–2030)

Table 29 Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Table 30 Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Table 31 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France (2017–2030)

Table 32 Total Non-metastatic Cases of CSPC/HSPC in France (2017–2030)

Table 33 Total Metastatic Cases of CSPC/HSPC in France (2017–2030)

Table 34 Total Treated Cases of nmHSPC/CSPC in France (2017–2030)

Table 35 Total Treated Cases of nmHSPC/CSPC in France (2017–2030)

Table 36 Total Treated Cases of mHSPC/CSPC in France (2017–2030)

Table 37 Total Treated Cases of mCSPC/HSPC in France (2017–2030)

Table 38 Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Table 39 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Table 40 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (2017–2030)

Table 41 Total Non-metastatic Cases of CSPC/HSPC in Italy (2017–2030)

Table 42 Total Metastatic Cases of CSPC/HSPC in Italy (2017–2030)

Table 43 Total Treated Cases of nmHSPC/CSPC in Italy (2017–2030)

Table 44 Total Treated Cases of nmHSPC/CSPC in Italy (2017–2030)

Table 45 Total Treated Cases of mHSPC/CSPC in Italy (2017–2030)

Table 46 Total Treated Cases of mCSPC/HSPC in Italy (2017–2030)

Table 47 Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Table 48 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Table 49 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (2017–2030)

Table 50 Total Non-metastatic Cases of CSPC/HSPC in Spain (2017–2030)

Table 51 Total Metastatic Cases of CSPC/HSPC in Spain (2017–2030)

Table 52 Total Treated Cases of nmHSPC/CSPC in Spain (2017–2030)

Table 53 Total Treated Cases of nmHSPC/CSPC in Spain (2017–2030)

Table 54 Total Treated Cases of mHSPC/CSPC in Spain (2017–2030)

Table 55 Total Treated Cases of mCSPC/HSPC in Spain (2017–2030)

Table 56 Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Table 57 Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Table 58 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom (2017–2030)

Table 59 Total Non-metastatic Cases of CSPC/HSPC in the United Kingdom (2017–2030)

Table 60 Total Metastatic Cases of CSPC/HSPC in the United Kingdom (2017–2030)

Table 61 Total Treated Cases of nmHSPC/CSPC in the United Kingdom (2017–2030)

Table 62 Total Treated Cases of nmHSPC/CSPC in the United Kingdom (2017–2030)

Table 63 Total Treated Cases of mHSPC/CSPC in the United Kingdom (2017–2030)

Table 64 Total Treated Cases of mCSPC/HSPC in the United Kingdom (2017–2030)

Table 65 Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Table 66 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Table 67 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (2017–2030)

Table 68 Total Non-metastatic Cases of CSPC/HSPC in Japan (2017–2030)

Table 69 Total Metastatic Cases of CSPC/HSPC in Japan (2017–2030)

Table 70 Total Treated Cases of nmHSPC/CSPC in Japan (2017–2030)

Table 71 Total Treated Cases of nmHSPC/CSPC in Japan (2017–2030)

Table 72 Total Treated Cases of mHSPC/CSPC in Japan (2017–2030)

Table 73 Total Treated Cases of mCSPC/HSPC in Japan (2017–2030)

Table 74 Marketed Key Cross of Prostate Cancer

Table 75 Xtandi (Enzalutamide), Clinical Trial Description, 2020

Table 76 Erleada (apalutamide), Clinical Trial Description, 2020

Table 77 Opdivo (nivolumab), Clinical Trial Description, 2020

Table 78 Relugolix, Clinical Trial Description, 2020

Table 79 Keytruda (Pembrolizumab/MK-3475), Clinical Trial Description, 2020

Table 80 PRX302 (topsalysin), Clinical Trial Description, 2020

Table 81 RV001V, Clinical Trial Description, 2020

Table 82 ProstAtak, Clinical Trial Description, 2020

Table 83 7MM Market Size of Prostate Cancer in USD Million (2017–2030)

Table 84 7MM Market Size of Prostate Cancer by Types, in USD Million (2017–2030)

Table 85 7MM Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 86 United States Market Size of Prostate Cancer by Types, in USD Million (2017–2030)

Table 87 United States Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 88 Germany Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 89 France Market Size of CSPC, in USD Million (2017–2030)

Table 90 France Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 91 Italy Market Size of CSPC, in USD Million (2017–2030)

Table 92 Italy Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 93 Spain Market Size of CSPC, in USD Million (2017–2030)

Table 94 Spain Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 95 United Kingdom, Market Size of CSPC, in USD Million (2017–2030)

Table 96 United Kingdom Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 97 Japan Market Size of CSPC, in USD Million (2017–2030)

Table 98 Japan Market Size of CSPC by Therapies, in USD Million (2017–2030)

Table 99 National Institute for Health and Care Excellence (NICE) Decisions for Prostate Cancer Therapies

Table 100 Haute Autorité de santé (HAS) Decisions for Prostate Cancer Therapies

Table 101 IQWiG Decisions for Prostate Cancer Therapies


List of Figures:

Figure 1 CSPC/HSPC SWOT Analysis

Figure 2 Prostate Cancer

Figure 3 Sign and Symptoms of Prostate Cancer

Figure 4 Risks Factors of Prostate Cancer

Figure 5 Pathophysiology of Prostate Cancer

Figure 6 Progression of Prostate Cancer and the Development of mCSPC/HSPC

Figure 7 Diagnosis of Prostate Cancer

Figure 8 Gleason Score of Prostate Cancer

Figure 9 Global Heat Map of Prostate Cancer

Figure 10 Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)

Figure 11 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–2030)

Figure 12 Total Non-metastatic Cases of CSPC in the 7MM (2017–2030)

Figure 13 Total Metastatic Cases of CSPC in the 7MM (2017–2030)

Figure 14 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in the 7MM (2017–2030)

Figure 15 Total Treated Cases of mCSPC/HSPC by Line of Therapies in the 7MM (2017–2030)

Figure 16 Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)

Figure 17 Age-specific Cases of Prostate Cancer in the United States (2017–2030)

Figure 18 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States (2017–2030)

Figure 19 Total Non-metastatic Cases of CSPC in the United States (2017–2030)

Figure 20 Total Metastatic Cases of CSPC in the United States (2017–2030)

Figure 21 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in the United States (2017–2030)

Figure 22 Total Treated Cases of mCSPC/HSPC by Line of Therapies in the United States (2017–2030)

Figure 23 Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Figure 24 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Figure 25 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany (2017–2030)

Figure 26 Total Non-metastatic Cases of CSPC in Germany (2017–2030)

Figure 27 Total Metastatic Cases of CSPC in Germany 2017–2030)

Figure 28 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in Germany (2017–2030)

Figure 29 Total Treated Cases of mCSPC/HSPC by Line of Therapies in Germany (2017–2030)

Figure 30 Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Figure 31 Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Figure 32 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France (2017–2030)

Figure 33 Total Non-metastatic Cases of CSPC in France (2017–2030)

Figure 34 Total Metastatic Cases of CSPC in France2017–2030)

Figure 35 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in France (2017–2030)

Figure 36 Total Treated Cases of mCSPC/HSPC by Line of Therapies in France (2017–2030)

Figure 37 Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Figure 38 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Figure 39 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (2017–2030)

Figure 40 Total Non-metastatic Cases of CSPC in Italy (2017–2030)

Figure 41 Total Metastatic Cases of CSPC in Italy 2017–2030)

Figure 42 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in Italy (2017–2030)

Figure 43 Total Treated Cases of mCSPC/HSPC by Line of Therapies in Italy (2017–2030)

Figure 44 Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Figure 45 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Figure 46 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (2017–2030)

Figure 47 Total Non-metastatic Cases of CSPC in Spain (2017–2030)

Figure 48 Total Metastatic Cases of CSPC in Spain (2017–2030)

Figure 49 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in Spain (2017–2030)

Figure 50 Total Treated Cases of mCSPC/HSPC by Line of Therapies in Spain (2017–2030)

Figure 51 Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Figure 52 Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Figure 53 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom (2017–2030)

Figure 54 Total Non-metastatic Cases of CSPC in the United Kingdom (2017–2030)

Figure 55 Total Metastatic Cases of CSPC in the United Kingdom (2017–2030)

Figure 56 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in the United Kingdom (2017–2030)

Figure 57 Total Treated Cases of mCSPC/HSPC by Line of Therapies in the United Kingdom (2017–2030)

Figure 58 Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Figure 59 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Figure 60 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (2017–2030)

Figure 61 Total Non-metastatic Cases of CSPC in Japan (2017–2030)

Figure 62 Total Metastatic Cases of CSPC in Japan (2017–2030)

Figure 63 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in Japan (2017–2030)

Figure 64 Total Treated Cases of mCSPC/HSPC by Line of Therapies in Japan (2017–2030)

Figure 65 Localized Disease Treatment Algorithm

Figure 66 High-risk Localized and Locally Advanced Disease Treatment Algorithm

Figure 67 Metastatic Disease Treatment Algorithm

Figure 68 Suggested Treatment Paradigm for Molecular Biomarkers in Advanced Prostate Cancer

Figure 69 Summary of Recommendations

Figure 70 Unmet Needs

Figure 71 Major mechanisms of therapeutic resistance to androgen axis-targeting therapies in prostate cancer

Figure 72 Market Size of CSPC in the 7MM Countries in USD Million (2017–2030)

Figure 73 Market Size of CSPC by Therapies in the 7MM, in USD Millions (2017–2030)

Figure 74 Market Size of CSPC in the United States, in USD Millions (2017–2030)

Figure 75 Market Size of CSPC by Therapies in the United States, in USD Millions (2017–2030)

Figure 76 Market Size of CSPC in Germany, in USD Millions (2017–2030)

Figure 77 Market Size of CSPC by Therapies in Germany, in USD Millions (2017–2030)

Figure 78 Market Size of CSPC in France, in USD Millions (2017–2030)

Figure 79 Market Size of CSPC by Therapies in France, in USD Millions (2017–2030)

Figure 80 Market Size of CSPC in Italy, in USD Millions (2017–2030)

Figure 81 Market Size of CSPC by Therapies in Italy, in USD Millions (2017–2030)

Figure 82 Market Size of CSPC in Spain, in USD Millions (2017–2030)

Figure 83 Market Size of CSPC by Therapies in Spain, in USD Millions (2017–2030)

Figure 84 Market Size of CSPC in the United Kingdom, in USD Millions (2017–2030)

Figure 85 Market Size of CSPC by Therapies in the United Kingdom, in USD Millions (2017–2030)

Figure 86 Market Size of CSPC in Japan, in USD Millions (2017–2030)

Figure 87 Market Size of CSPC by Therapies in the Japan, in USD Millions (2017–2030)

Figure 88 Market Drivers

Figure 89 Market Barriers

Bristol-Myers Squibb

Myovant Sciences/Takeda

Merck Sharp & Dohme

Sophiris Bio

RhoVac

Advantagene

  • Tags:
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...
  • Castrate-Sensitive Prostate Cancer...

Forward to Friend

Need A Quote